The case for combining angiotensinconverting enzyme inhibitors and calcium-channel blockers

Current Hypertension Reports

Volumn 1, Issue 5, 1999, Pages 446-453

  Taylor, Addison A ^a   Sunthornyothin, Sarat ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES COMPLICATIONS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS;

EID: 0033205705     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0062-1     Document Type: Article

References (76)

1. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703-713. This substudy of a large clinical trial to evaluate treatment of type II diabetes in 4297 patients focused on a comparison of aggressive versus more lax control of blood pressure. Tight blood pressure control was associated with a significant reduction in deaths and complications of diabetes, including progression of diabetic nephropathy.
2. Hebert LA, Kusek JW, Greene T, et al.: Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997, 30:428-435.
3. Bakris GL: Progression of diabetic nephropathy: a focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract 1998, 39(suppl):S35-S42. This is an excellent recent review of the data supporting the value of aggressive blood pressure control among patients with diabetes in delaying the progression of nephropathy.
4. Lewis EJ, Hunsicker LG, Bain R P, et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
5. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al.: Antiproteinuric effect of blood-pressure-lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963-1974.
6. Johnston CI, Risvanis J, Naitoh M, et al.: Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens 1998, 16(suppl 4):S3-S7. This publication succinctly reviews the known and proposed hemodynamic mechanisms that are involved in hypertensive nephropathy. It is one of a series of reviews in the same journal (see Benigni and Remuzzi [7]).
7. Benigni A, Remuzzi G: Mechanisms of progression of renal disease: growth factors and related mechanisms. J Hypertens 1998, 16(suppl 4):S9-S12. The focus of this short review is on mechanisms by which protein in the tubule is thought to be toxic and on the potential role of endothelin in the development of glomerulosclerosis, independent of its vasoconstrictor effects.
8. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997, 12:2244-2250.
9. Epstein M: The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixeddose combination antihypertensive therapy. Ren Fail 1996, 18:813-832.
10. Epstein M: Calcium antagonists and renal protection: emerging perspectives. J Hypertens 1998, 16(suppl 4):S17-S25. A comprehensive review of the mechanisms thought to contribute to the progression of renal disease and of the documented and potential therapeutic benefits of ACE inhibitors and calcium-channel blockers in modulating that progression in both experimental animal and human investigations.
11. Tesfamariam B, Cohen RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992, 263:H32-H326.
12. Bakris GL, Williams B: Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995, 13(suppl 2):S95-S101.
13. Carmines PK, Navar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar response to Ang II. Am J Physiol 1989, 256:F1015-F1020.
14. Fujiwara Y, Kitamura E, Ueda N, et al.: Mechanism of action of angiotensin II on isolated rat glomeruli. Kidney Int 1989, 36:985-991.
15. Orth SR, Nobiling R, Bönisch S, Ritz E: Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. Kidney Int 1996, 49:868-879.
16. Welch WJ, Wilcox CS, Thomson SC: Nitric oxide and tubuloglomerular feedback. Semin Nephrol 1999, 19:251-262.
17. Schnackenberg CG, Granger JP: Verapamil abolishes the preglomerular response to ANG II during intrarenal nitric oxide synthesis inhibition. Am J Physiol 1997, 272:R1670-R1676.
18. Zhang X, Hintze TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998, 97:576-580.
19. Mason R P, Walter MF, Trumbore MW, et al.: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999, 31:275-281.
20. Karam H, Heudes D, Bruneval P, et al.: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: comparison with angiotensin- converting enzyme inhibition and calcium antagonism. Hypertension 1996, 28:379-385.
21. Huang S, Simonson MS, Dunn MJ: Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J 1993, 125:589-597.
22. D'Uscio LV, Shaw S, Barton M, et al.: Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension 1998, 31:1305-1310.
23. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993-2000.
24. Anderson S, Rennke HG, Garcia DL, et al.: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989, 36:526-536.
25. Ruggenenti P, Perna A, Mosconi L, et al.: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998, 53:1209-1216.
26. Brown SA, Walton CL, Crawford P, et al.: Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993, 43:1210-1218.
27. Stefanski A, Amann K, Ritz E: To prevent progression: ACE inhibitors, calcium antagonists or both? Nephrol Dial Transplant 1995, 10:151-153.
28. Gallego B, Flores O, Lopez-Novoa JM, et al.: Renal effects of antihypertensive therapy in uninephrectomized diabetic rats. Res Exp Med (Berl) 1997, 197:199-209.
29. Munter K, Hergenroder S, Jochims K, et al.: Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol 1996, 7:681-686.
30. Fioretto P, Frigato F, Velussi M, et al.: Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992, 5:837-846.
31. Bakris G, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992, 41:912-919.
32. Bakris GL, Weir MR, Dequattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combinationon proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283-1289. This open-label clinical trial of combined ACE inhibitor (trandolapril) and calcium-channel blocker (verapamil) versus monotherapy with each agent in hypertensive diabetics with proteinuria demonstrated a greater reduction in proteinuria with the combination than with either agent alone. This additive effect appeared to be independent of the blood pressure because the reduction in blood pressure was not greater with the combination than with either agent alone. The results differ from those obtained by Hemmelder et al. [33].
33. Hemmelder MH, De Zeeuw D, De Jong PE: Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 1999, 14:98-104. This recent study compares the antiproteinuric effect of an ACE inhibitor (trandolapril) -calcium channel blocker (verapamil) combination with each drug alone in patients with renal disease, most of whom were normotensive. The findings suggest that the antiproteinuric effect of verapamil may be related entirely to its effect on systemic blood pressure, whereas the reduction in protein excretion that occurred with trandopapril was greater than that attributable to its antihypertensive effect.
34. Weir MR: The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens 1998, 11:163S-169S.
35. Gasowski J, Staessen JA, Celis H, et al.: Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. J Hum Hypertens 1999, 13:135-145.
36. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [published erratum appears in N Engl J Med 1994, 330:1689.] N Engl J Med 1993, 328:914-921.
37. Bakris GL: The role of combination antihypertensive therapy and the progression of renal disease hypertension. Am J Hypertens 1998, 11:158S-162S.
38. Kuschnir E, Acuna E, Sevilla D, et al.: Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996, 18:1213-1224.
39. Frishman WH, Ram CV, McMahon FG, et al.: Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995, 35:1060-1066.
40. Gradman AH, Cutler NR, Davis PJ, et al.: Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997, 79:431-435.
41. Dal Ponte DB, Fogt DL, Jacob S, et al.: Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism 1998, 47:982-987. This is one of the few studies to compare the effects of ACE inhibitor-calcium-channel blockers combined therapy versus monotherapy on metabolic parameters. The combination of captopril and verapamil improved insulin sensitivity in obese Zucker rats more than either agent alone. Less dramatic results were obtained in diabetics (see Rett et al. [42]).
42. Rett K, Jacob S, Wicklmayr M: Possible synergistic effect of ACE inhibition and calcium-channel blockade on insulin sensitivity in insulin-resistant type II diabetic hypertensive patients. J Cardiovasc Pharmacol 1994, 23(suppl 1):S29-S33.
43. Perico N, Amuchastegui CS, Malanchini B, et al.: Angiotensinconverting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 1994, 2:220-228.
44. Rumble JR, Doyle AE, Cooper ME: Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. Am J Hypertens 1995, 8:53-57.
45. Anderson S, Meyer TW, Rennke HG, et al.: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985, 76:612-619.
46. Gaber L, Walton C, Brown S, Bakris G: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994, 46:161-169.
47. Meyer TW, Anderson S, Rennke HG, et al.: Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency. Am J Med 1985, 79:31-36.
48. Flores O, Arevalo M, Gallego B, et al.: Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp Nephrol 1998, 6:39-49.
49. Kanno Y, Okada HSH, Ikenaga H, et al.: Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats? Clin Exp Hypertens 1996, 18:243-256.
50. Bakris GL: Renal effects of calcium antagonists in diabetes mellitus: an overview of studies in animal models and in humans. Am J Hypertens 1991, 4(suppl):487S-493S.
51. Kvam FI, Ofstad J, Iversen BM: Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. Am J Physiol 1998, 275:F576-F584.
52. Kanno Y, Suzuki H, Okada H, et al.: Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol 1994, 23:480-484.
53. Dworkin LD, Tolbert E, Recht PA, et al.: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996, 27:245-250.
54. Jyothirmayi GN, Reddi AS: Effect of diltiazem on glomerular heparan sulfate and albuminuria in diabetic rats. Hyp ertension 1993, 21:795-802.
55. Girardi G, Elias MM: Verapamil protection against mercuric chloride-induced renal glomerular injury in rats. Toxicol Appl Pharmacol 1998, 152:360-365.
56. Bakris GL, Griffin KA, Picken MM, et al.: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997, 15:1181-1185.
57. Wenzel UO, Helmchen U, Schoeppe W, et al.: Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994, 23:114-122.
58. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or analapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998, 31:801.
59. Llinas MT, Gonzalez JD, Rodriguez F, et al.: Renal changes induced by nitric oxide and prostaglandin synthesis reduction: effects of trandolapril and verapamil. Hypertension 1998, 31:657-664.
60. Crepaldi G, Carta Q, Deferrari G, et al.: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998, 21:104-110.
61. Agardh CD, Garcia-Puig J, Charbonnel B, et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996, 10:185-192.
62. Bohlen L, De Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hyperten 1994, 7:84S-92S.
63. Fogari R, Zoppi A, Corradi L, et al.: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999, 13:47-53.
64. Rudberg S, Osterby R, Bangstad HJ, et al.: Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:589-595.
65. Nankervis A, Nicholls K, Kilmartin G, et al.: Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998, 47:12-15.
66. Maschio G, Alberti D, Locatelli F, et al.: Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999, 33(suppl 1):S16-S20.
67. Ruggenenti P, Perna A, Benini R, et al.: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998, 9:2096-2101.
68. Maschio G, Marcantoni C: Angiotensin converting enzyme inhibitors in nondiabetic renal disease. Curr Opin Nephrol Hypertens 1998, 7:253-257.
69. Ihle BU, Whitworth JA, Shahinfar S, et al.: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996, 27:489-495.
70. O'Donnell MJ, Rowe BR, Lawson N, et al.: Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens 1993, 7:333-339.
71. Bilo H, Kluitman E, Van Ballegooie E, et al.: Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 1993, 23:115-122.
72. Jansen JJW M, Gans ROB, Van Der Meulen J, et al.: Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure. Am J Hypertens 1998, 11:1074-1079.
73. Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889-896.
74. Dequattro V, Lee DP: Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt. Cardiology 1997, 88(suppl 3):38-42.
75. Hemmelder MH, De Zeeuw D, De Jong PE: Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 1999, 14:98-104.
76. Bakris G, White D: Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997, 11:35-38.